A phase I study of 5-azacytidine (Vidaza) [azacitidine] with interferon alpha 2b in metastatic melanoma patients

Trial Profile

A phase I study of 5-azacytidine (Vidaza) [azacitidine] with interferon alpha 2b in metastatic melanoma patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2007

At a glance

  • Drugs Azacitidine (Primary) ; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Dec 2007 The expected completion date for this trial is now 1 May 2007, reported by ClinicalTrials.com.
    • 14 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top